← Search & browse all drugs

tuberculin

V04CF01

Forms & Strengths

Purified Protein Derivative (PPD) vial, 5 TU/0.1 mL
PPD vial, 10 TU/0.1 mL
PPD vial, 100 TU/1 mL
Lyophilized powder for reconstitution

Adult Dosing

Mantoux test: 0.1 mL intradermally (5 TU) injected into forearm skin
Serial testing (e.g., conversion): 0.1 mL intradermally (2 TU)
Therapeutic tuberculin (for warts, TB prophylaxis): 0.1 mL intradermally (5 TU) weekly for 3 weeks then monthly

Pediatric Dosing

Mantoux test (≥2 years): 0.1 mL intradermally (5 TU)
Infants (<2 years): 0.05 mL intradermally (2.5 TU) if test required
Therapeutic use: same as adult dose, adjusted to body surface area if large area treatment

Indications

Screening for latent Mycobacterium tuberculosis infection (Mantoux tuberculin skin test)
Detection of conversion in high‑risk contacts
Monitoring response to anti‑TB therapy (serial testing)
Therapeutic tuberculin for cutaneous warts, lupus vulgaris, and as adjunct in TB prophylaxis

Mechanism of Action

PPD contains multiple mycobacterial antigens that trigger a delayed‑type (type IV) hypersensitivity reaction in previously sensitized T‑cells
Resulting induration reflects cell‑mediated immunity against M. tuberculosis

Contraindications

Known severe hypersensitivity to tuberculin or any PPD component
Active, untreated TB disease (test not indicated)
Severe immunosuppression where test reliability is compromised (e.g., CD4 < 200 cells/µL)

Adverse Reactions

Local erythema, induration, ulceration, or necrosis at injection site
Lymphadenitis of draining nodes
Systemic fever, malaise
Rare anaphylactoid reaction

Drug Interactions

Systemic corticosteroids, TNF‑α inhibitors, azathioprine, and other immunosuppressants may diminish induration size
Live vaccines (e.g., BCG) can cause false‑positive tuberculin test
Interferon‑γ release assays are not affected and can be used adjunctively

Curated Content: Needs Vetting Before Put to Clinical Use